Monoclonal antibodies targeting cancer: 'magic bullets' or just the trigger?
The first monoclonal antibodies (mAbs) approved for cancer therapy are now in Phase II and III trials, but the critical mechanism(s) determining efficacy and response in patients are still largely undefined. Both the direct antigen-binding (Fab) and constant (Fc) regions of mAbs can contribute to th...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
BioMed Central
2001
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC138676/ |